

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 1 of 16
6.3 Effect on Tobacco Use Initiation Among Non-Users	Version 1.0

Module 6 : Research

6.3 Effect on Tobacco Use Initiation Among Non-Users

TABLE OF CONTENTS

1.	INFORMATION ON TOBACCO USE INITIATION AMONG NON-USERS.....	3
1.1.	Premarket U.S. data	3
1.1.1.	Background.....	3
1.1.2.	Effect of THS Label, Labeling and Marketing Material on Behavioral Intentions among Adult Non-Smokers	3
1.1.3.	Conclusion of U.S. Pre-market Studies	4
1.2.	Postmarket U.S. Data.....	5
1.2.1.	Background.....	5
1.2.2.	U.S. Postmarket Data among Tobacco Non-Users from IQOS Cross-sectional PACS	5
1.2.3.	U.S. Postmarket Data on Underage Awareness, Ever Use, And Past 30-Day Use of the IQOS System from UTUS analysis	8
1.2.1.	Conclusion of U.S. Postmarket studies.....	11
1.3.	PMP S.A. International Postmarket Data: Repeated Cross-sectional Post-Market Surveys (PMX studies).....	11
1.3.1.	Background.....	11
1.3.2.	PMP S.A. International Postmarket Data on initiation, relapse and re-initiation.....	12
1.3.3.	Conclusion of International Postmarket studies	14
1.4.	Independent Studies	14
1.4.1.	Background.....	14
1.5.	Conclusion	15
2.	REFERENCES	16

Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 2 of 16
6.3 Effect on Tobacco Use Initiation Among Non-Users	Version 1.0

LIST OF TABLES

Table 1	Types of tobacco products ever tried, used to lifetime criterion, and currently using, among current <i>IQOS</i> users.....	6
Table 2	Initiation with <i>IQOS</i> among Long-Term Former Established Smokers and Long-Term Former Established Users of All Tobacco Products.....	7
Table 3	Methodology of Analysis of Relevant Data from the ALCS Underage Tobacco Use Survey	9
Table 4	UTUS 2022 to 2023 Estimates: Awareness, Ever Use, and Past 30-Day Use of <i>IQOS</i>	11
Table 5	Initiation, Relapse rate, and Re-initiation rate with <i>IQOS</i> among adult TNP non-users in representative samples of the cross-sectional general adult population and <i>IQOS</i> Owners’ surveys in Japan and Italy.....	13

Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 3 of 16
6.3 Effect on Tobacco Use Initiation Among Non-Users	Version 1.0

1. INFORMATION ON TOBACCO USE INITIATION AMONG NON-USERS

To measure the potential benefit of marketing an MRTP to the public, the FDA Modified Risk Tobacco Product Applications Guidance recommended investigating several areas, including the effect on tobacco use initiation among non-users¹. In this section, we provide data from both pre-market studies included in the original MRTPA², and postmarket studies conducted both within the U.S. and internationally, on the effect of *IQOS* on tobacco use initiation among non-users. In addition, we cross-reference Module 7 of the initial MRTPA for the Authorized *IQOS* products with related appendices and data, and with subsequent amendments, and Module 7 of the supplemental PMTA for the Authorized *IQOS* 3 System (PM0000634), as well as Module 7 of the supplemental MRPTA for the *IQOS* 3 System (MR0000192).

1.1. Premarket U.S. data

1.1.1. Background

To provide data on the effect on tobacco use initiation among non-users, PMI conducted a U.S. premarket quantitative study (THS-PBA-05-REC-US) to assess the effect of the authorized reduced exposure claim, included as part of the THS Label, Labeling and Marketing Materials (LLM), on behavioral intentions among adult tobacco non-users. A summary of the methodology of this study is presented in section 6-2 (Table 1).

Below, we provide a brief summary of previously submitted evidence from this U.S. pre-market quantitative study on behavioral intentions among adult tobacco non-users.

1.1.2. (b) (4)

(b) (4)

¹ FDA. Modified Risk Tobacco Product Applications. Guidance for Industry. Rockville, MD: U.S. Department of Health and Human Services. March 2012.
<https://www.fda.gov/downloads/TobaccoProducts/Labeling/RulesRegulationsGuidance/UCM297751.pdf>.

² MRTPA Modified Risk Granted Order - Exposure Modification of December 12, 2019, authorizing the marketing of the modified risk product *IQOS* 2.4 System Holder and Charger (STN: MR0000133).

(b) (4)

Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 4 of 16
6.3 Effect on Tobacco Use Initiation Among Non-Users	Version 1.0

(b) (4)

1.1.3. Conclusion of U.S. Pre-market Studies

Based on the above data that was previously submitted to the FDA as part of the original MRTPA (MR0000059-MR0000061, MR0000133), the FDA TPL review⁵ determined that

- *Among former smokers: the results suggest some interest in trying the product among former smokers, but the addition of the claim did not appear to increase interest among this group. Accordingly, the results do not suggest that the products, if marketed with a reduced exposure claim, would generate a high level of interest among former smokers. This finding is consistent with a potential benefit to population health.*
- *Among adult never smokers: the results suggest almost no interest in trying the product among adult never smokers, and the addition of the reduced exposure claim did not appear to increase interest among this group. Accordingly, the results do not raise concerns that the proposed MRTP would generate a high level of interest among never smokers. This finding is consistent with a potential benefit to population health.*
- *Among young adult never smokers: the evidence related to young adult never smokers suggests low interest in trying the product. In the applicant's studies, the addition of the claim did not appear to increase interest in trying IQOS. Accordingly, the results do not raise concerns that the proposed MRTP would generate a high level of interest among young adult never smokers. This finding is consistent with a potential benefit to population health.*

(b) (4)

⁵ Scientific Review of Modified Risk Tobacco Product Application (MRTPA) Under Section 911(d) of the FD&C Act – Technical Project Lead, p. 62, July 6, 2020.

Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 5 of 16
6.3 Effect on Tobacco Use Initiation Among Non-Users	Version 1.0

(b) (4)

1.2. Postmarket U.S. Data

1.2.1. Background

As part of the PMSS program for IQOS pursuant to the MRGOs orders from the FDA, PMP S.A. has developed a comprehensive post-market surveillance program within the United State that permits evaluation of the impact of the marketing of the IQOS System (b) (4)

is provided in

Section 8.1. (b) (4)

1.2.2. U.S. Postmarket Data among Tobacco Non-Users from IQOS Cross-sectional PACS


(b) (4)

Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 6 of 16
6.3 Effect on Tobacco Use Initiation Among Non-Users	Version 1.0

Table 1 Types of tobacco products ever tried, used to lifetime criterion, and currently using, among current *IOOS* users



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 7 of 16
6.3 Effect on Tobacco Use Initiation Among Non-Users	Version 1.0

(b) (4)

Table 2 Initiation with IQOS among Long-Term Former Established Smokers and Long-Term Former Established Users of All Tobacco Products

(b) (4)


^s (b) (4)

Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 8 of 16
6.3 Effect on Tobacco Use Initiation Among Non-Users	Version 1.0

1.2.3. U.S. Postmarket Data on Underage Awareness, Ever Use, And Past 30-Day Use of the IQOS System from UTUS analysis



(b) (4)

[Redacted text block consisting of three lines of greyed-out content]

Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 9 of 16
6.3 Effect on Tobacco Use Initiation Among Non-Users	Version 1.0

Table 3 Methodology of Analysis of Relevant Data from the ALCS Underage Tobacco Use Survey

(b) (4)

Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 10 of 16
6.3 Effect on Tobacco Use Initiation Among Non-Users	Version 1.0



(b) (4)

Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.


Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 11 of 16
6.3 Effect on Tobacco Use Initiation Among Non-Users	Version 1.0

Table 4 UTUS 2022 to 2023 Estimates: Awareness, Ever Use, and Past 30-Day Use of IQOS



1.3. PMP S.A. International Postmarket Data: Repeated Cross-sectional Post-Market Surveys (PMX studies)

1.3.1. Background



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 12 of 16
6.3 Effect on Tobacco Use Initiation Among Non-Users	Version 1.0

(b) (4)

1.3.2. *PMP S.A. International Postmarket Data on initiation, relapse and re-initiation*

(b) (4)

¹⁴(b) (4)

Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 13 of 16
6.3 Effect on Tobacco Use Initiation Among Non-Users	Version 1.0

Table 5 Initiation, Relapse rate, and Re-initiation rate with IQOS among adult TNP non-users in representative samples of the cross-sectional general adult population and IQOS Owners' surveys in Japan and Italy


(b) (4)

Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.


Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 14 of 16
6.3 Effect on Tobacco Use Initiation Among Non-Users	Version 1.0

1.3.3. Conclusion of International Postmarket studies



1.4. Independent Studies

1.4.1. Background



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 15 of 16
6.3 Effect on Tobacco Use Initiation Among Non-Users	Version 1.0

(b) (4)

1.5. Conclusion

(b) (4)

(b) (4)

Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 16 of 16
6.3 Effect on Tobacco Use Initiation Among Non-Users	Version 1.0

2. REFERENCES

Afolalu, E.F., Langer, P., Fischer, K., Roulet, S. and Magnani, P., 2021. Prevalence and patterns of tobacco and/or nicotine product use in Japan (2017) after the launch of a heated tobacco product (IQOS®): a cross-sectional study. F1000Research, 10.

Fischer, K., Bajec, M., Mainy, N., AlMoosawi, S., Sieverding, M., Zwisele, B., Camille, N., Magnani, P. and Roulet, S., 2022. Trends in prevalence and patterns of use of a heated tobacco product (IQOS™) in Japan: A three-year repeated cross-sectional study. F1000Research, 11(720), p.720.

Gentzke et al., Tobacco Product Use and Associated Factors Among Middle and High School Students - United States, 2020 MMWR Morb Mortal Wkly Rep.2020; 69(50): 1881-1888.

Gentzke, A.S., Wang, T.W., Cornelius, M., Park-Lee, E., Ren, C., Sawdey, M.D., Cullen, K.A., Loretan, C., Jamal, A. and Homa, D.M., 2022. Tobacco product use and associated factors among middle and high school students—National Youth Tobacco Survey, United States, 2021. MMWR Surveillance Summaries, 71(5), p.1.

Park-Lee et al. Tobacco Product Use Among Middle and High School Students — United States, 2022 MMWR Morb Mortal Wkly Rep 2022;71(45): 1429-1435.

Wang TW, Gentzke AS, Creamer MR, Cullen KA, Holder-Hayes E, Sawdey MD, Anic GM, Portnoy DB, Hu S, Homa DM, Jamal A, Neff LJ. Tobacco Product Use and Associated Factors Among Middle and High School Students - United States, 2019. MMWR Surveill Summ. 2019 Nov 6;68(12):1-22. doi: 10.15585/mmwr.ss6812a1. PMID: 31805035; PMCID: PMC6903396.

Zhang, L., Gentzke, A., Trivers, K.F. and VanFrank, B., 2022. Tobacco cessation behaviors among US middle and high school students, 2020. Journal of Adolescent Health, 70(1), pp.147-154.

Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.
